Background: Potentially driver-impairing (PDI) medications have been associated with poorer driving performance and increased risk of motor vehicle collision. Objectives: To describe the frequency of medication use and to determine the association between routine use of PDI medications and performance on driving and cognitive tests. Methods: A total of 225 drivers with medical impairment (mean age 68 ± 12.8 years, 62.2% male) were referred to an occupational therapy-based driving evaluation clinic. Medication lists were reviewed to identify PDI drugs, as defined by a previous study examining medications and crash risk. Outcome variables included road testing on the modified Washington University Road Test and cognitive scores on Trail Making Test Parts A and B, Snellgrove Maze Task, Clock Drawing Task, Driving Health Inventory (DHI) Useful Field of View, DHI Motor Free Visual Perceptual Test, Epworth Sleepiness Scale (ESS), Geriatric Depression Scale, and Functional Assessment Questionnaire. Results: PDI medication use was documented in 68.9% of the sample, with the average subject taking 1.4 PDI drugs. Drivers taking routine PDI medications had a mean ESS score of 7.8 compared to 6.0 in the control group, suggesting increased somnolence (P = .007). Total number of routine medications, regardless of PDI designation, also correlated positively with ESS scores (P = .023). Conclusions: Use of PDI medications was associated with informant ratings of daytime drowsiness on the ESS, which has been linked to motor vehicle crash risk. Further investigation of individual drug classes is warranted using larger sample sizes and a high-powered study design.
Introduction
Polypharmacy is common in adults >65 years of age. 1 However, more concerning than the total number of drugs being taken is the use of routine medications with central nervous system (CNS) side effects. Various classes of drugs have been implicated in sedation and driving impairment, and their corresponding adverse effects have been described in the literature. [2] [3] [4] Central depressant effects of these agents have a greater impact on older adult patients as compared with their younger, healthier counterparts. 5 This discrepancy is part of the rationale behind the Beers List, which has raised clinician awareness of the ability for potentially driver-impairing (PDI) medications to impair performance more overtly in older adult drivers. 5 Notwithstanding, review of therapeutic regimens has revealed that such drugs are commonly prescribed to older adult patients under care of the medical community. 6, 7 Pharmacokinetic characteristics such as lipid solubility may confer more long-term deleterious effects on driving when medications are retained in the body for a longer period. Even infrequent use may pose a hazard to driving with agents exhibiting very long half-lives. Implications of this phenomenon may include delayed or slowed reaction time; impaired selective, divided, or sustained attention; dizziness; drowsiness; hypersomnolence; tremor; ataxia; or confusion and delirium. 8 Impairments in many of these cognitive domains have been associated with increased risk of motor vehicle crash. 9, 10 We are not aware of any studies examining the impact of PDI drugs in driving evaluation referral patients with medical comorbidities. It is also unknown whether use in this setting is associated with impaired psychometric performance and/or driving ability. The primary objective of this study was to describe the frequency of PDI medication use within the sample and to determine whether an association exists between use of PDI medications and hypersomnolence, depression, cognition, and driving performance. We hypothesized that use of PDI medications in medically ill drivers would be associated with poorer performance on these outcomes.
Methods
This study was approved by the Human Studies Committee at Washington University in compliance with the 1975 Declaration of Helsinki. A total of 249 patients were referred by physicians for concerns raised regarding the ability to safely operate an automobile. Patients were assessed at The Rehabilitation Institute of St Louis (TRISL) Driving Connections Clinic for evaluation between January 2008 and May 2012. Recruitment occurred with several separately funded studies on dementia, stroke, glaucoma, and general neurological disease. The studies were designed to determine whether certain off-road psychometric tests were predictive of driving performance and could be used as screens for determining driving competency. 11, 12 Recruitment was promoted through letters to Washington University clinicians, e-mails, newsletters, brochures, and visits to the local chapter of the Alzheimer's Association.
The fitness-to-drive studies required the presence of an informant (typically a spouse or adult child) because the primary reasons for referral were often diseases such as dementia or stroke, which might impair decision-making capacity and the ability to accurately answer questionnaires. Consent was obtained with the participant and informant at the time of the driving assessment.
Each informant was first contacted for a 20-minute telephone screen to determine study eligibility and obtain a medication history. The clinical and behind-the-wheel driving evaluation was then scheduled within 1 to 2 months. To be eligible, patients had to be at least 25 years old and have the following: 10 or more years of driving experience, an active license to drive, English-speaking ability, and a primary medical condition with physician referral for evaluation of fitness to drive. Patients with unstable illness (eg, recent seizure), severe physical deformity, or a sensory or communication deficit were excluded out of safety concerns (n = 5). Explicit refusal to participate or follow road test instructions or a history of any other driving evaluation within the past 12 months also excluded patients from the study. Several patients were excluded for incomplete diagnostic criteria, where AD-8 (n = 2, a brief interview to identify signs of dementia) or NIHSS (n = 17, a rating scale to classify stroke severity) were not performed. These constraints brought the final sample size to 225.
Retrospective analysis began with the creation of a master PDI medication list based on results of a previous study 13 in addition to a literature search using keywords such as collision, driving, crash, impairment, or motor vehicle along with names of the drug classes (eg, terms like benzodiazepine driving). This reference study, conducted by LeRoy and Morse 13 in 2008, included more than 33 000 drivers who had been involved in motor vehicle crashes and more than 100 000 drivers without recent motor vehicle crash claims to serve as the control group. To be classified as PDI, medications had to demonstrate a statistically significant odds ratio (OR) ≥1.25 in the LeRoy and Morse 13 report. To support the clinical significance of medications with a documented OR between 1.25 and 1.49, the investigators stipulated that the associated risk of driving impairment be corroborated by at least one other source.
Review and classification of each patient's medications was performed by one investigator (AJH) and coded using a unique numbering system. The investigator was blinded to outcome measures during this process. Variables included total number of routine medications, total number of routine PDI medications, and use of specific classes of PDI medications, with the latter variable to stratify PDI medication use for additional data analyses. Both prescription and over-thecounter medications were included regardless of dosage form or administration site. Minerals, vitamins, herbals and dietary supplements, oxygen therapy, and diabetic testing supplies were not counted as medications. Combination medications (eg, levodopa/carbidopa) were counted by the total number of active ingredients rather than as a single agent. Out of more than 1300 total routine medications documented on 225 medication lists, only 3 were omitted for illegibility. Additionally, 3 medication histories did not distinguish between routine or as-needed use for any of the listed drugs; however, these were consistent with drugs prescribed for routine use and were included in the data set.
The 90-minute psychometric assessment portion was conducted at TRISL prior to the on-road evaluation and included tests of vision, cognition, and motor function ( Table 1) . Cognitive tests included the Short Blessed Test, 14 the Clock Drawing Task (CDT), 15 Trail Making Test Parts A (TMT-A) and B (TMT-B), 16 Snellgrove Maze Task, 17 and 2 subtests from the Driving Health Inventory (DHI)-Useful Field of View and the Motor Free Visual Perceptual Test. 18, 19 For all cognitive tests except the CDT, higher scores indicate greater impairment. Informants were present to provide responses for the Epworth Sleepiness Scale (ESS), 20 Geriatric Depression Scale, 21 and Functional Assessment Questionnaire (FAQ).
The modified Washington University Road Test (mWURT) 11 was a secondary outcome measure in this study. Lasting approximately 60 minutes, the 12-mile course used many unprotected left-hand turns, along with complex merges and intersections in the later aspects of the route. The road test involved an initial closed course in a large parking lot, allowing participants to become familiar with the car and surroundings. After demonstrating proficiency, participants were instructed to proceed out of the lot into the open course (ie, traffic). Qualitative ratings of pass, marginal, and fail were given by an instructor in the front seat. Pass and marginal grades were merged to provide a dichotomous rating of pass or fail.
Statistical Analysis
Statistical analysis was performed by one investigator (MJW) using SAS 9.3 22 and involved group comparisons between patients taking at least 1 PDI medication and those taking none. Because the principal objective of this study was descriptive, the TMT-A was selected as the primary cognitive outcome for power calculation. A sample of 155 patients taking PDI medications and 70 patients not on PDI medications would provide 80% power with a 2-tailed t test (α = .05) when the true mean TMT-A difference is 13.7 s. Simple comparisons of PDI groups were made with the Pearson χ 2 test for categorical outcomes and 2-sample t tests for continuous outcome variables. Analysis of variance or multivariable logistic regression was used to control for dementia (n = 102) and stroke (n = 80), the most prevalent medical impairments prompting referral. Finally, the study compared outcome measures among individual PDI medication classes to determine whether any classes were more strongly associated with cognitive or driving impairment. Groups were reassigned according to use versus nonuse of a specific class.
Results
Demographics and clinical screens are outlined in Table 2 . Each measure provides data based on the entire sample, group-specific data from both PDI and non-PDI users, and P values reflecting the comparison between the latter 2 columns. Because several components of the FAQ were not performed or not obtained during patient interviews, data for this variable became difficult to examine and are, therefore, excluded from our analyses. The use of PDI medications was associated with higher scores on the ESS (absolute difference = 1.8; 95% CI = 0.6 to 3.1; P = .007), a difference which remained after controlling for medical impairment. Total number of routine medications, regardless of PDI designation, also correlated positively with ESS scores (P = .023). There were no other statistically significant differences on psychometric test scores or on mWURT performance. The average medically impaired driver was taking 5.9 ± 3.7 total routine medications, 1.4 of which were PDI drugs; 68.9% (n = 155) of the sample was on at least 1 routine PDI medication. The most prevalent subclasses included selective serotonin reuptake inhibitors (SSRIs; 30.7%), proton pump inhibitors (PPIs; 17.8%), hypoglycemic agents (16.9%), and antiepileptic drugs (11.5%), whereas some others were rarely reported (Table 3) . Dementia, stroke, and glaucoma were the most frequent referral diagnoses, accounting in total for 85% of the sample. Hypertension was the most common medical comorbidity, although it was not indicated as a primary cause for referral in any patient ( Table 4 ).
The next set of analyses focused on the PDI subclasses of drugs to determine if there were differences in any major outcome measures. Few significant differences were noted within any of the medication classes on outcome measures. Of note, higher ESS scores were observed in patients taking nonsteroidal anti-inflammatory drugs (absolute difference = 3.6; P = .042) and antiparkinsonians (absolute difference = 3.8; P < .001); patients taking second-generation antidepressants exhibited worse performance on the CDT (absolute difference = 0.95; P = .040). No other differences were detected owing to a small sample size further narrowed by the infrequent use of many PDI medications, including barbiturates (n = 1) and firstgeneration antihistamines (n = 2).
Discussion
Based on these descriptive findings, polypharmacy and PDI medication use was evident in considerably more than half of the sample. This reflects comorbidities in these drivers and, possibly, the common practice of multiple prescribing for individual diagnoses. A higher ESS mean score in patients prescribed PDI drugs is concerning, because daytime drowsiness on this scale has been associated with an increased risk of motor vehicle crashes in some studies. 20, 23 The sample of medically impaired older adults often had conditions that could alone affect driving ability (eg, sleep apnea). Thus, clinicians who encounter these patients should review past medical histories to appropriately consider the potential additive impact of prescribing sedating drugs.
In this sample, it is interesting to note a nonsignificant trend toward a higher fail rate in drivers using no routine PDI medications. Although this could be attributed to the small sample size or perhaps severity of the medical illness outweighing PDI medication effects, it is also possible that certain drugs may have had a positive impact on driving ability, especially those drugs that treat pain or restricted mobility (eg, antiparkinsonians). Medications may, of course, improve cognition, attention, and mobility, which could be another important focus for further study in older adults. 
Study Limitations
Some limitations to this study should be addressed. First, all medications designated as PDI were grouped into 1 category, recognizing that certain agents may have a less potent impact on driving than others, and some may even impart benefits to performance, as discussed previously.
Although a moderate association was demonstrated in the LeRoy and Morse 13 study, classes such as SSRIs and PPIs are not typically reported to have major CNS sedating effects, creating potential to distort or dilute the results. In fact, some authors only assign sedating properties to specific drugs in these classes (eg, paroxetine and omeprazole). 24 Additionally, advanced age or the primary medical impairment warranting referral may have masked any potential additive impact of PDI medications. Drug compliance in this type of retrospective study could not be ensured or confirmed. Medication use was documented 1 to 2 months prior to evaluation and might have changed within that time frame; thus, it could have been helpful to document timing of the last dose before evaluation. It is also possible that patients, in anticipation of the driving evaluation, may have refrained from taking medicationssuspected to negatively affect test performance.
Finally, this convenience sample was built on a series of driving studies that focused on recruiting participants in specific disease categories (eg, dementia, stroke, and glaucoma), and participants were not required to pay for the driving evaluation. The small sample size precluded the use of motor vehicle crashes as an outcome and may have limited our ability to find differences, especially when performing analyses on smaller subsets of drug classes. We also acknowledge that qualitative road test scores (eg, pass vs fail) may not be as sensitive as a quantitative error count to detect in-traffic performance decrements. In light of the relatively small sample size, we believe that additional research is needed to confirm which specific PDI medication classes actually affect driving, and under what circumstances. Studies of larger samples in a variety of settings are needed to clarify the role of medications in driving performance in medically impaired older adults.
Conclusion
Polypharmacy and the use of PDI medications were common in this sample. Use of these drugs was associated with higher informant ratings of daytime drowsiness on the ESS, a tool that has been linked to motor vehicle crash risk. 9 In lieu of multiple prescribing to medically impaired patients referred for driving evaluation, we recommend that clinicians review medication lists to aid in reducing or eliminating sedating CNS medications. This practice to lessen medication burden could have a positive impact on driving performance in older adults. However, what actually constitutes a PDI drug requires further research. In the literature on prescription drugs and driving, it is often difficult to determine whether drug or disease is to blame where driving competency is questioned. Whether certain drugs would enhance or impair driving performance in older adults remains an unanswered question, and which specific drugs should be labeled as PDI merits additional study and clarification.
